GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction — VialBase Research
high
- GLP-1 users had significantly lower composite wound complication rates than non-users (9.0% vs 17.1%, p = 0.002) after free flap breast reconstruction
- Reduced surgical site infections (4.1% vs 8.1%, p = 0.026) and wound dehiscence (3.8% vs 7.8%, p = 0.023) in GLP-1 users
- No differences in debridement, seroma, or hematoma rates between groups
- Benefit was concentrated in non-diabetic patients (7.9% vs 18.6% composite complications, p = 0.007); diabetic subgroup showed comparable rates between users and non-users
- Preoperative GLP-1 use was not linked to increased wound complications — supports safety when used perioperatively
GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction
Summary
Retrospective cohort study from University of Utah using the TriNetX Research Network (global de-identified EHR database) to evaluate whether preoperative GLP-1 receptor agonist use (Semaglutide, Tirzepatide, liraglutide, dulaglutide, exenatide) is associated with postoperative wound complications in adults undergoing free flap breast reconstruction from 2012–2025. Used 1:1 propensity score matching to control for confounders, with subgroup analysis by diabetes status.
The headline finding: GLP-1 users had roughly half the composite wound complication rate of non-users (9.0% vs 17.1%), driven by lower surgical site infections and wound dehiscence. The benefit was concentrated in non-diabetic patients, suggesting mechanisms beyond glycemic control may be at work.
Key Findings
- Composite wound complication rate: 9.0% (GLP-1 users) vs 17.1% (non-users), p = 0.002
- Surgical site infection: 4.1% vs 8.1%, p = 0.026
- Wound dehiscence: 3.8% vs 7.8%, p = 0.023
- No difference in debridement, seroma, or hematoma rates
- Non-diabetic subgroup: 7.9% vs 18.6% composite, p = 0.007
- Diabetic subgroup: rates comparable between users and non-users
Methodology
- Retrospective cohort, TriNetX Research Network
- Adults ≥18 undergoing free flap breast reconstruction 2012–2025, identified by CPT codes
- GLP-1 exposure defined as prescription within 1 year before surgery
- 1:1 propensity score matching, then outcome analysis on matched cohorts
- Diabetes-status subgroup analysis
Limitations
- Retrospective, observational — residual confounding likely despite propensity matching
- EHR-based, so GLP-1 adherence and actual dose not verified
- Breast reconstruction population may not generalize to other surgical settings
- Mechanism of benefit not established; the disappearance of the effect in diabetics hints at something specific to the non-diabetic metabolic context
- Sample size not explicit in abstract
Relevance to Content
For the VialBase audience — many of whom are using GLP-1 agonists off-label for weight management — this is a useful data point pushing back on the narrative that perioperative GLP-1 use is uniformly risky. Most recent concerns about GLP-1s around surgery center on anesthesia aspiration risk (gastric retention — see tirzepatide-gastric-retention-case-report-preprint), not wound healing. This paper suggests that for elective reconstructive procedures, the wound-healing concern is not borne out, and the signal may actually run in favor of preoperative GLP-1 exposure.
Useful for:
- A guide on “peptides and surgery” addressing aspiration risk AND wound-healing data together
- Citation in Tirzepatide and Semaglutide profile perioperative sections